Floatz logo

Grt-C901

Colorectal Neoplasms

Gritstone bio, Inc.gene_therapyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB

View all 50 →

Same molecule, other indications

Grt-C901 is also rated in:

colonic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
gastroesophageal adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →
urothelial carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →